LONDON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, ...

Research will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation ...

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with advanced solid tumors who progressed on at least one prior regimen containing a ...

This open-label study included 19 patients from clinical sites in Ireland and the United States. The majority of patients were female (68.4%) and the average age was 42 years. The primary endpoint was ...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.